In brief: ResMed, Genesis, Genepharm, EG Capital

Sleep disorder specialist company ResMed (ASX:RMD) has promoted Kieran Gallahue from president and American chief operating officer to president of ResMed Global.

Gallahue will temporarily relocate to ResMed's Sydney offices as he makes the transition into his new role. He will assume responsibility for global operations, new business development, and product innovation.

He joined ResMed in January 2003 from San Diego-based Nanogen

Agrigenesis chief resigns

Genesis Research and Development (ASX:GEN) today announced that Dr Peter Lee would step down as chief executive of the firm's subsidiary, AgriGenesis, handing control of the company to Genesis Research chief executive Dr Jim Watson.

His resignation follows an unsuccessful bid by AgriGenesis to raise capital, and the termination of a number of research programs at AgriGenesis.

"The market for new investment in agricultural biotechnology is not strong, so it was necessary to focus our resources on the highest priority projects," said Watson.

Genepharm appoints sales and marketing director

Generic medicines company Genepharm Australasia (ASX:GAA) has appointed former GlaxoWellcome sales and marketing director Keith Jeffs as director of sales and marketing. Jeffs has also held the positions of sales and marketing director and chief executive.

eG Capital appoints chairman

Biotech investment bank eG Capital has appointed Peter Forbes as the chairman of its board of directors.

Forbes was the former deputy CEO and executive general manager of equities for Queensland Investment Corporation, a group well known for its investments into the Australian biotech sector. His appointment is effective immediately.